Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952655774> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2952655774 endingPage "430" @default.
- W2952655774 startingPage "430" @default.
- W2952655774 abstract "Background: Additional salvage regimens are burdensome for relapsed/refractory acute lymphoblastic leukemia (ALL) patients (pts) due to therapy-associated toxicities, which may affect quality of life with poor efficacy. In INO-VATE (Kantarjian et al, NEJM 2016), pts receiving inotuzumab ozogamicin (InO) vs standard chemotherapy (SC) had significantly greater remission rates and longer overall survival; after study treatment discontinuation, overall fewer subsequent induction/salvage therapies (STs, mainly burdensome chemotherapies) were used in the InO group vs SC. Aims: To investigate the treatment of InO on the time to the first ST (TST) in the INO-VATE trial. Methods: Study design was published. Adults with CD22+ ALL who were due to receive 1st or 2nd salvage treatment were randomized 1:1 to InO (n = 164) or SC (n = 162). TST was time from randomization to the start of the first ST. Pts who did not receive any ST were censored. Data cutoff: Jan 4, 2017. Results: Fewer InO pts had ST vs SC pts (Table). Among the censored pts, 83/108 (76.9%) in the InO vs 54/69 (78.3%) in the SC group died, 23/108 (21.3%) vs 5/69 (7.2%) were alive at the end of the study, and 2/108 (1.9%) vs 10/69 (14.5%) were no longer being followed for survival. TST was longer in pts receiving InO vs SC. Overall median (95% CI) TST was 18.8 (14.7–NA) vs 3.9 (2.4–5.1) months; hazard ratio (HR) = 0.34, 97.5% CI: 0.23–0.49, 1-sided P < 0.0001. For pts (InO: 85, SC: 126) who never received hematopoietic stem cell transplantation (HSCT) on study, fewer InO pts had ST vs SC pts; TST was significantly longer in InO vs SC. For pts (InO: 70, SC: 18) who had HSCT directly after salvage, TST was extended in InO vs SC.Summary/Conclusion: In this study, treatment with InO provided the benefit of extended TST, effectively allowing patients a longer time period until an ST was needed in both patients who proceeded to as well as those who did not proceed to HSCT." @default.
- W2952655774 created "2019-06-27" @default.
- W2952655774 creator A5008245160 @default.
- W2952655774 creator A5044372572 @default.
- W2952655774 creator A5049007772 @default.
- W2952655774 creator A5060255938 @default.
- W2952655774 creator A5061052240 @default.
- W2952655774 creator A5085676625 @default.
- W2952655774 creator A5086504056 @default.
- W2952655774 creator A5091635008 @default.
- W2952655774 date "2019-06-01" @default.
- W2952655774 modified "2023-09-26" @default.
- W2952655774 title "PS955 FEASIBLE OUTCOME OF BLINATUMOMAB FOLLOWED BY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH RELAPSED OR REFRACTORY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA" @default.
- W2952655774 doi "https://doi.org/10.1097/01.hs9.0000562092.00325.67" @default.
- W2952655774 hasPublicationYear "2019" @default.
- W2952655774 type Work @default.
- W2952655774 sameAs 2952655774 @default.
- W2952655774 citedByCount "0" @default.
- W2952655774 crossrefType "journal-article" @default.
- W2952655774 hasAuthorship W2952655774A5008245160 @default.
- W2952655774 hasAuthorship W2952655774A5044372572 @default.
- W2952655774 hasAuthorship W2952655774A5049007772 @default.
- W2952655774 hasAuthorship W2952655774A5060255938 @default.
- W2952655774 hasAuthorship W2952655774A5061052240 @default.
- W2952655774 hasAuthorship W2952655774A5085676625 @default.
- W2952655774 hasAuthorship W2952655774A5086504056 @default.
- W2952655774 hasAuthorship W2952655774A5091635008 @default.
- W2952655774 hasBestOaLocation W29526557741 @default.
- W2952655774 hasConcept C121332964 @default.
- W2952655774 hasConcept C126322002 @default.
- W2952655774 hasConcept C141071460 @default.
- W2952655774 hasConcept C142424586 @default.
- W2952655774 hasConcept C207103383 @default.
- W2952655774 hasConcept C2776694085 @default.
- W2952655774 hasConcept C2778020697 @default.
- W2952655774 hasConcept C2778461978 @default.
- W2952655774 hasConcept C2778715236 @default.
- W2952655774 hasConcept C2780775027 @default.
- W2952655774 hasConcept C2909962599 @default.
- W2952655774 hasConcept C44249647 @default.
- W2952655774 hasConcept C71924100 @default.
- W2952655774 hasConcept C87355193 @default.
- W2952655774 hasConcept C90924648 @default.
- W2952655774 hasConceptScore W2952655774C121332964 @default.
- W2952655774 hasConceptScore W2952655774C126322002 @default.
- W2952655774 hasConceptScore W2952655774C141071460 @default.
- W2952655774 hasConceptScore W2952655774C142424586 @default.
- W2952655774 hasConceptScore W2952655774C207103383 @default.
- W2952655774 hasConceptScore W2952655774C2776694085 @default.
- W2952655774 hasConceptScore W2952655774C2778020697 @default.
- W2952655774 hasConceptScore W2952655774C2778461978 @default.
- W2952655774 hasConceptScore W2952655774C2778715236 @default.
- W2952655774 hasConceptScore W2952655774C2780775027 @default.
- W2952655774 hasConceptScore W2952655774C2909962599 @default.
- W2952655774 hasConceptScore W2952655774C44249647 @default.
- W2952655774 hasConceptScore W2952655774C71924100 @default.
- W2952655774 hasConceptScore W2952655774C87355193 @default.
- W2952655774 hasConceptScore W2952655774C90924648 @default.
- W2952655774 hasIssue "S1" @default.
- W2952655774 hasLocation W29526557741 @default.
- W2952655774 hasLocation W29526557742 @default.
- W2952655774 hasOpenAccess W2952655774 @default.
- W2952655774 hasPrimaryLocation W29526557741 @default.
- W2952655774 hasRelatedWork W2528057197 @default.
- W2952655774 hasRelatedWork W2890700631 @default.
- W2952655774 hasRelatedWork W2914292410 @default.
- W2952655774 hasRelatedWork W2971349430 @default.
- W2952655774 hasRelatedWork W2987501148 @default.
- W2952655774 hasRelatedWork W3021403523 @default.
- W2952655774 hasRelatedWork W3044534343 @default.
- W2952655774 hasRelatedWork W3108928978 @default.
- W2952655774 hasRelatedWork W3131174609 @default.
- W2952655774 hasRelatedWork W3139239827 @default.
- W2952655774 hasVolume "3" @default.
- W2952655774 isParatext "false" @default.
- W2952655774 isRetracted "false" @default.
- W2952655774 magId "2952655774" @default.
- W2952655774 workType "article" @default.